Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Targeted sequencing panel IDs Lynch syndrome in women with/at risk for endometrial cancer

Publish date:: May 22, 2019

Key clinical point: Targeted Lynch syndrome sequencing panel rapidly IDs Lynch syndrome pathogenic mutations.

Major finding: Lynch syndrome prevalence may be 6-7 times greater than the current estimate of 3% to 5%.

Study details: An analysis of a next-generation sequencing panel in 71 patients.

Disclosures: Dr. Padron reported having no relevant financial disclosures.

Citation:

REPORTING FROM ACOG 2019

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,